Getinge AB B

Getinge is engaged in three business areas: Medical Systems, Extended Care and Infection Control. Medical System's product range includes surgical tables, surgical lamps, telemedicine, perfusion products, instruments for bypass operations, ventilators, anesthesia systems, synthetic vascular implants and stents. Extended Care's product range includes bathing and shower solutions, lifting equipment and mattresses for the treatment and prevention of pressure ulcers, as well as service and consulting. Infection Control's product range comprises disinfectors, sterilizers, information technology systems and related equipment, as well as service and consulting.
  • TickerGETI B
  • ISINSE0000202624
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Frank Maaø ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Patrik Ling

Getinge (Hold, TP: SEK85.00) - Expect GM pressure to continue

We expect Getinge to report continued strong sales growth in Q4. However, we believe the gross margin should continue to be under pressure due to the negative product and geographical sales mix. Thus, we reiterate our HOLD recommendation and SEK85 target price. Results are due at 13:00 CET on 30 January.

Marius Knudssøn ...
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Patrik Ling

Getinge (Hold, TP: SEK85.00) - Limited news at CMD

Getinge hosted a CMD on 21 November. In our view, there was limited news presented at this event. It reiterated its financial guidance of 2–4% organic growth, >10% growth in EPS and its dividend policy of 30–50% of net income. The company did not give any additional information on the mesh issue or any timelines for when we should see margins recover. It was clear that a rights issue will not be necessary to strengthen the balance sheet. We reiterate our HOLD and SEK85 target price.

1 director bought

A director at Getinge Ab bought 26,509 shares at 81.830SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Patrik Ling

Getinge (Hold, TP: SEK85.00) - Expect GM pressure to continue

We expect Getinge to report continued strong sales growth in Q4. However, we believe the gross margin should continue to be under pressure due to the negative product and geographical sales mix. Thus, we reiterate our HOLD recommendation and SEK85 target price. Results are due at 13:00 CET on 30 January.

Patrik Ling

Getinge (Hold, TP: SEK85.00) - Limited news at CMD

Getinge hosted a CMD on 21 November. In our view, there was limited news presented at this event. It reiterated its financial guidance of 2–4% organic growth, >10% growth in EPS and its dividend policy of 30–50% of net income. The company did not give any additional information on the mesh issue or any timelines for when we should see margins recover. It was clear that a rights issue will not be necessary to strengthen the balance sheet. We reiterate our HOLD and SEK85 target price.

Patrik Ling

Getinge (Hold, TP: SEK85.00) - Another soft and messy quarter

Getinge reported Q3 earnings on 18 October. The overall report was weaker than expected but given the recently announced large reserve the company took for the North American mesh litigation, it is hard to compare reported earnings to actual expectations. We have reduced our target price significantly to SEK85 (SEK100) on the recent developments as we believe that the shares are more risky now than in the past. We retain our HOLD recommendation.

Jake Strole

Morningstar | Getinge's 3Q Results Show Continuation of Strong Growth on Weaker Margins; Maintaining FVE

No-moat Getinge reported another quarter defined by encouraging revenue growth but deteriorating margin performance. That said, we're comfortable with our longer-term cash flow projections, and we don't intend to change our SEK 94 fair value estimate after incorporating third-quarter results. Organic sales growth of 7.2% for the quarter and 6.2% year to date far outpaced our expectations for full-year performance close to the low end of management's reiterated 2%-4% target. While this range now appears too conservative for the year, we're not comfortable taking up our longer-term growth forec...

Jake Strole

Getinge's 3Q Results Show Continuation of Strong Growth on Weaker Margins; Maintaining FVE

No-moat Getinge reported another quarter defined by encouraging revenue growth but deteriorating margin performance. That said, we're comfortable with our longer-term cash flow projections, and we don't intend to change our SEK 94 fair value estimate after incorporating third-quarter results.  Organic sales growth of 7.2% for the quarter and 6.2% year to date far outpaced our expectations for full-year performance close to the low end of management's reiterated 2%-4% target. While this range now...

1 director bought

A director at Getinge Ab bought 26,509 shares at 81.830SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Frank Maaø ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Marius Knudssøn ...
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Antti Kansanen ...
  • Eivind Sars Veddeng
  • Joachim Gunell
  • Jon Masdal
  • Martin Arnell
  • Martin Huseby Karlsen
  • Niclas Gehin
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Jon Masdal
  • Marius Knudssøn
  • Martin Arnell
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Paul Harper
  • Simen Mortensen

Northern Lights

Nurhayati Wan

Getinge

null

Nurhayati Wan

Getinge

Nurhayati Wan

Getinge

null

Nurhayati Wan

Getinge

null

GETINGE AB with less fundamental stars is reduced to Neutral

GETINGE AB (SE), a company active in the Medical Equipment industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 3 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date September 25, 2018, the closing price was SEK 107.60 and its expected value was estimated at SEK 102....

GlobalData Department

Getinge AB (GETI B) - Medical Equipment - Deals and Alliances Profile

Summary Getinge AB (Getinge) is a medical technology company that designs, develops and markets equipment and instruments in the areas of surgery, infection control, intensive care, care ergonomics and wound care. Its major products include surgical tables, lights, ventilators and anesthesia equipment, heart-lung machines with accompanying disposables, equipment and instruments for cardiac surgery, vascular surgery; cardiac assist devices; patient lifting devices, hospital beds, stretchers and couches, mattresses for treating and preventing pressure sores, disinfectors, sterilization equipmen...

GlobalData Department

Getinge AB (GETI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Getinge AB (Getinge) is a medical technology company that designs, develops and markets equipment and instruments in the areas of surgery, infection control, intensive care, care ergonomics and wound care. Its major products include surgical tables, lights, ventilators and anesthesia equipment, heart-lung machines with accompanying disposables, equipment and instruments for cardiac surgery, vascular surgery; cardiac assist devices; patient lifting devices, hospital beds, stretchers and couches, mattresses for treating and preventing pressure sores, disinfectors, sterilization equipmen...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/12/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting.Under ITEM 7, the board of directors seeks approval to distribute all shares in the wholly-owned subsidiary Arjo to the Company's shareholders. ECGS endorses the view of the board of directors that the proposal to split the Company into two separate listed companies (Getinge and Arjo) could enhance the prerequisites to succesfully develop the respective businesses. In addition, ECGS is generally supportive towards corporate spin-offs as they give s...

Expert Corporate Governance Service (ECGS)

Etude l' AG du 15/08/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting. Under ITEM 7, it is proposed to add a conversion clause, providing the opportunity to convert series A shares into series B shares, to the Company's Articles of Association. As a matter of principle, we welcome the addition of such a conversion clause. The clause is intended to facilitate the spin-off of the Company's Acute Care Therapies business ("Arjo") to its shareholders. Under the Swedish Companies Act conversion is only possible on a 1:1 basi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch